• Explore /
  • Poster
  • / A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).

Abstract Poster

Authors

Lyudmila Bazhenova

Lyudmila Bazhenova

University of California, San Diego, La Jolla, CA

Lyudmila Bazhenova , Mary Weber Redman , Scott N. Gettinger , Fred R. Hirsch , Philip C. Mack , Lawrence Howard Schwartz , David R. Gandara , Jeffrey D. Bradley , Tom Stinchcombe , Natasha B. Leighl , Suresh S. Ramalingam , Susan S Tavernier , Katherine Minichiello , Karen Kelly , Vassiliki Papadimitrakopoulou , Roy S. Herbst

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

02785952

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9014)

DOI

10.1200/JCO.2019.37.15_suppl.9014

Abstract #

9014

Poster Bd #

337

Abstract Disclosures

Similar Posters

First Author: Edwin R. Parra

First Author: Christos Chouaid

First Author: Kohei Shitara

First Author: Robert E. Smith